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Baseline	albumin-bilirubin	(ALBI)	in	Western	patients	with	hepatocellular	
carcinoma	treated	with	stereotactic	body	radiotherapy	
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Summary	
	
In	a	prospective	series	of	102	Western	patients	with	Child	Pugh	A	hepatocellular	
carcinoma	 (HCC)	 managed	 with	 stereotactic	 body	 radiotherapy	 (SBRT),	 the	
baseline	albumin-bilirubin	(ALBI)	score	was	evaluated	as	a	predictor	of	survival	
and	 hepatic	 toxicity.	 ALBI	was	 an	 independent	 significant	 predictor	 of	 toxicity	
and	 survival,	 and	 was	more	 discriminating	 than	 Child	 Pugh	 score.	 Thus,	 ALBI	
warrants	 further	 investigation	 and	 should	 be	 included	 as	 a	 factor	 for	
stratification	in	future	clinical	trials.	
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Abstract	
	
Purpose:	To	assess	the	baseline	albumin-bilirubin	(ALBI)	grade	as	a	predictor	of	
toxicity	 and	 survival	 in	 a	 prospective	 cohort	 of	 Western	 patients	 with	
hepatocellular	 carcinoma	 (HCC)	 treated	 with	 stereotactic	 body	 radiotherapy	
(SBRT)	in	two	prospective	trials.		
	
Methods	 and	 materials:	 102	 patients	 with	 Child	 Pugh	 A	 liver	 disease	 who	
received	 6-fraction	 SBRT	 for	 HCC	were	 included.	 Univariate	 and	multivariable	
logistic	 regression	 investigated	 factors	 associated	 with	 toxicity,	 defined	 as	 an	
increase	 in	 Child	 Pugh	 score	 of	 ≥2	 within	 3	 months	 of	 SBRT.	 Univariate	 and	
multivariable	 Cox	 regression	 investigated	 factors	 predictive	 of	 overall	 survival	
(OS).	 ALBI	 was	 analysed	 as	 a	 continuous	 and	 binary	 variable	 in	 separate	
analyses.	
	 	
Results:		
On	multivariable	 analysis	 of	 toxicity,	 including	 ALBI	 as	 a	 continuous	 variable,	
ALBI	 (odds	 ratio	 (OR)	 per	 0.1	 unit	 increase:	 1.51	 (95%	 confidence	 interval	
(CI):1.23-1.85,	 p=0.00074),	 mean	 liver	 dose	 (OR:1.31	 (95%CI:1.02-1.68),	
p=0.036)	 and	 dose	 received	 by	 800cc	 of	 normal	 liver	 (D800)	 (OR:1.10	
(95%CI:1.01-1.20,	 p=0.028),	 were	 significant.	 When	 including	 ALBI	 as	 a	
dichotomous	 variable,	 ALBI	 grade	 remained	 a	 significant	 predictor	 of	 toxicity	
(OR:7.44	(95%CI:2.34-23.70,	p=0.00069).	
	
On	multivariable	 analysis	 of	OS,	 including	ALBI	 as	 a	 continuous	 variable,	 ALBI	
(Hazard	 ratio	 (HR)	 per	 0.1	 increase:	 1.09	 (95%CI:1.03-1.17,	 p=0.004),	 tumour	
thrombus	(HR:1.94	(95%CI:1.23-3.07,	p=0.004)	and	being	treated	in	Trial	1	vs.	2	
(HR:1.92	 (95%CI:1.23-3.03),	 p=0.004)	 were	 significant.	 Similarly,	 when	
including	 ALBI	 as	 a	 binary	 variable,	 ALBI,	 tumour	 thrombus	 and	 trial	 were	
significant	predictors	of	OS.	
	
When	ALBI	was	considered,	Child	Pugh	score	(A6	vs	A5)	was	not	significant	 in	
multivariable	 models	 analysing	 toxicity	 or	 survival.	 Concordance	 statistics	
indicated	models	containing	ALBI	were	superior	to	those	containing	Child	Pugh.	
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Conclusions:	Baseline	ALBI	was	more	discriminating	 than	Child	Pugh	score	 in	
predicting	 OS	 and	 toxicity	 in	 patients	 with	 Child	 Pugh	 A	 liver	 disease.	 ALBI	
should	be	used	as	a	factor	for	stratification	in	future	HCC	SBRT	trials.		
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Introduction	
	
Patients	with	 hepatocellular	 cancer	 (HCC)	who	 are	 unsuitable	 for	 resection	 or	
radiofrequency	 ablation	 (RFA)	 may	 be	 appropriate	 for	 stereotactic	 body	
radiotherapy	 (SBRT).	 	 The	 Child	 Pugh	 (CP)	 score	 is	 a	 convenient	 bedside	 tool,	
frequently	used	to	assess	cirrhosis	severity	and	predict	survival	in	patients	with	
liver	disease,	 and	also	often	used	 to	guide	HCC	patient	 selection	 for	 treatment,	
including	SBRT.	Most	often	SBRT	is	reserved	for	patients	with	Child	Pugh	A	(CP-
A)	disease,	while	more	 caution	 is	 required	 in	 treating	 those	with	Child	Pugh	B	
(CP-B)	disease,	where	toxicity	is	more	common1.		
	
Despite	 its	ease	of	use,	there	are	disadvantages	in	the	CP	score2,3,	 including	the	
subjective	 nature	 of	 determining	 the	 degree	 of	 ascites	 and	 severity	 of	
encephalopathy,	 and	 the	 discretising	 of	 the	 continuous	 variables	 within	 the	
scoring	 system	 (bilirubin,	 albumin	 and	 INR)	 resulting	 in	 information	 loss2,4.	 In	
addition,	 the	ceiling	 levels	 for	each	component	were	chosen	empirically,	 rather	
than	being	based	on	definite	changes	in	outlook	between	categories2,4.	There	has	
also	 been	 concern	 regarding	 the	 appropriateness	 of	 CP	 for	 assessing	 liver	
dysfunction	in	HCC,	as	it	was	originally	designed	for	assessing	surgical	outcomes	
in	 patients	 with	 bleeding	 oesophageal	 varices5.	 Furthermore,	 some	 factors	
within	the	scoring	system	may	be	correlated	(e.g.	albumin	and	ascites)	and	other	
potentially	important	factors	(e.g.	creatinine)	are	not	included2,6,7.	The	inclusion	
of	ascites	within	the	CP	score	further	limits	its	usefulness	in	HCC	where	vascular	
invasion	may	 increase	portal	pressure	 leading	 to	ascites,	due	 to	 tumour	 rather	
than	liver	dysfunction.	
	
More	 recently,	 Johnson	 et	 al	 described	 the	 albumin-bilirubin	 (ALBI)	 score	 for	
determining	 prognosis	 in	 HCC	 patients4.	 ALBI	 is	 calculated	 as	 a	 continuous	
variable	 using	 serum	 bilirubin	 and	 albumin	 and	 can	 be	 categorised	 into	 3	
prognostic	 groups.	 The	 ALBI	 model	 was	 developed	 from	 a	 cohort	 of	 1313,	
predominantly	 CP-A,	 Japanese	 HCC	 patients,	 then	 validated	 in	 >5000	 patients	
from	elsewhere.	It	has	been	suggested	that	ALBI	is	more	discriminating	than	CP	
score4.							
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Our	group	previously	evaluated	SBRT	in	a	cohort	of	CP-A	HCC	patients,	 treated	
within	 two	 prospective	 trials8.	Multivariable	 analysis	 identified	 two	 significant	
factors	 predictive	 of	 overall	 survival	 (OS):	 the	 presence/absence	 of	 tumour	
vascular	 thrombosis	 and	 whether	 patients	 were	 treated	 in	 Trial	 1	 or	 2,	 with	
patients	from	the	more	recent	trial	(Trial	2)	faring	better,	an	observation	which	
was	 unexplained.	 The	 CLIP	 score,	 which	 incorporates	 CP,	 HCC	 burden,	 alpha-
fetoprotein	 (AFP)	 and	 tumour	 thrombosis,	 was	 non-significant	 on	 univariate	
analysis8.	More	recently,	predictors	of	liver	toxicity	(defined	as	worsening	of	CP	
score	 by	 ≥2	 points	 within	 3	 months	 post-SBRT)	 were	 analysed	 for	 the	 same	
cohort.	Child	Pugh	score	A6	vs.	A5	and	 lower	platelet	 count	were	predictive	of	
increased	toxicity,	in	addition	to	dosimetric	factors	(mean	liver	dose	(MLD)	and	
D800)9.	
	
This	 report	aimed	 to	evaluate	baseline	ALBI	as	a	potential	predictor	of	hepatic	
toxicity	 and	 survival	 in	 HCC	 patients	 treated	with	 SBRT	 in	 the	 above	 trials.	 A	
secondary	 goal	 was	 to	 investigate	 if	 ALBI	 could	 account	 for	 the	 survival	
differences	observed	between	patients	in	Trial	1	and	2	in	the	original	analysis8.		
	
Methods	and	materials:		
	
Patients	
	
This	 analysis	 included	 102	 patients	 from	 two	 prospective	 trials	 investigating	
SBRT	 for	 HCC	 between	 2004	 and	 2010	 at	 Princess	 Margaret	 Cancer	 Centre,	
Toronto8.	 Preliminary	 clinical	 outcomes	 have	 been	 reported	 previously8.	 This	
analysis	 included	 the	 same	 cohort,	 with	 updated	 follow-up.	 Patients	 had	 CP-A	
baseline	 liver	 function	 and	 were	 deemed	 unsuitable	 for	 transplantation,	
resection,	 transarterial	 chemoembolization	 (TACE)	 and	 RFA.	 For	 patients	who	
had	 received	 previous	 liver	 directed	 therapies,	 eligibility	 for	 SBRT	 required	
progression	following	the	last	therapy.		
	
	
	 8	
Treatment	
	
Treatment	techniques	have	been	described	in	detail	previously8.	In	brief,	breath	
hold	 with	 active	 breathing	 control	 or	 abdominal	 compression	 was	 used	 to	
minimize	 respiratory	 motion	 when	 possible.	 The	 gross	 tumour	 volume	 (GTV)	
was	 visible	 HCC	 including	 any	 vascular	 invasion,	 defined	 using	 multiphasic	
intravenous	 contrast-enhanced	 planning	 CT	 and	 MRI.	 For	 most	 patients	 there	
was	no	expansion	 for	 clinical	 target	volume	 (CTV;	 i.e.	GTV=CTV).	The	planning	
target	 volume	 (PTV)	 was	 5mm	 for	 patients	 treated	 in	 breath	 hold.	 Patients	
treated	with	 abdominal	 compression	and	 free	breathing	had	an	 internal	 target	
volume	 based	 PTV.	 Prescription	 dose	 was	 individualized	 based	 on	 the	 liver	
effective	 volume	 irradiated	 (Veff).	 Treatment	 was	 delivered	 in	 6	 fractions	 on	
alternate	 days	 with	 daily	 volumetric	 image-guidance.	 Patients	 were	 reviewed	
every	3	months	with	clinical	examination,	blood	work	and	imaging.	
	
ALBI	
	
ALBI	was	calculated	from	baseline	blood	work	according	to	Johnson	et	al4:	
	
ALBI	=	(log10	bilirubin	x	0.66)	+	(albumin	x	-0.085)		
(bilirubin	measured	in	μmol/L,	albumin	in	g/L)	
	
The	following	cut-points	can	be	used	to	define	three	prognostic	groups:	
	
ALBI	grade	1:	≤-2.60	
ALBI	grade	2:	>-2.60	to	≤-1.39	
ALBI	grade	3:	>-1.39	
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Statistics	
	
Relationship	between	ALBI	and	CP	score	
	
The	 relationship	 between	 ALBI	 as	 a	 continuous	 variable	 and	 CP	 score	 was	
assessed	using	the	independent	samples	t-test.	The	Chi-square	test	was	used	to	
investigate	the	relationship	between	ALBI	as	a	binary	variable	(all	patients	had	
ALBI	grade	1	or	2)	and	CP	score.		
	
Toxicity	analysis	
	
Univariate	and	multivariable	logistic	regressions	were	performed	to	measure	the	
odds	 of	 developing	 toxicity,	 defined	 as	 an	 increase	 in	 CP	 score	 of	 ≥2	within	 3	
months	 of	 SBRT	 completion	 in	 the	 absence	 of	 definite	 HCC	 progression,	
according	to	RECIST	criteria,	version	1.1	Patients	who	developed	toxicity	prior	to	
disease	 progression	 were	 considered	 as	 having	 experienced	 a	 toxicity	 event.	
Patients	who	developed	toxicity	at	the	same	time	as	definite	progressive	disease	
were	excluded	from	this	toxicity	analysis,	since	HCC	progression	may	contribute	
to	 decline	 in	 CP	 score	 in	 these	 patients.	 The	 following	 baseline	 factors	 were	
tested	in	univariate	analysis:	age,	gender,	tumour	volume,	normal	 liver	volume,	
tumour	 thrombus	 (yes/no),	 CP	 score	 (A5/A6),	 platelet	 count,	 underlying	 liver	
disease	 (hepatitis	 B/C/other),	 previous	 liver	 directed	 therapy	 (yes/no),	 ALBI,	
prescribed	 dose,	MLD,	 Veff,	 physical	 and	 biological	 normal	 tissue	 complication	
probability	 (NTCP)10	 and	 dose	 received	 by	 800cc	 of	 liver	 (D800).	 Given	 the	
widely	accepted	importance	of	MLD	as	a	predictor	of	toxicity	in	HCC	treated	with	
radiotherapy9,11,	it	was	decided	a	priori	to	force	MLD	into	the	final	multivariable	
toxicity	model.	All	other	variables	with	p-values	<0.2	on	univariate	analysis	were	
also	 included	 in	 the	multivariable	 analysis	with	 the	 final	model	 selected	 using	
backwards	selection	(but	keeping	MLD	in	the	model).		
	
ALBI	was	 evaluated	 as	 both	 a	 continuous	 and	 binary	 variable	 in	 two	 separate	
analyses,	to	determine	the	utility	of	the	ALBI	system	in	both	formats.		
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To	exclude	multi-collinearity	between	variables,	variance	inflation	factors	(VIF)	
were	 calculated	 for	 covariates	 eligible	 for	 inclusion	 within	 the	 multivariable	
analysis.	Factors	with	VIF	>10.0	were	considered	indicative	of	multi-collinearity.	
Where	such	 factors	existed,	 these	were	reviewed	and	removed	as	necessary	 to	
avoid	multi-collinearity	 (i.e.	 only	 VIF	 <10.0	were	 included	 in	 the	multivariable	
analysis)12	
	
Survival	analysis	
	
Median	 time	 to	 death	 was	 calculated	 from	 the	 date	 of	 SBRT	 start	 using	 the	
Kaplan-Meier	 method.	 Univariate	 and	 multivariable	 hazard	 ratios	 were	
calculated	 using	 Cox	 Proportional-Hazards.	 Baseline	 age,	 gender,	 tumour	
volume,	 normal	 liver	 volume,	 tumour	 thrombus,	 CP	 score,	 platelet	 count,	
underlying	 liver	 disease,	 AFP,	 Eastern	 Cooperative	 Oncology	 Group	 (ECOG)	
Performance	Status	 (PS),	 extra-hepatic	disease	 (yes/no),	 trial,	ALBI,	prescribed	
dose	 and	 MLD	 were	 tested	 in	 univariate	 analysis.	 	 Variables	 with	 p<0.2	 on	
univariate	 analysis	 were	 included	 in	 the	 multivariable	 analysis,	 with	 the	 final	
model	selected	using	backwards	selection.		
	
	
As	 for	 logistic	 regression,	 ALBI	 was	 evaluated	 as	 both	 a	 continuous	 and	
dichotomous	variable	 in	 two	separate	analyses.	As	 for	 the	toxicity	analysis,	VIF	
were	calculated	to	guard	against	multi-collinearity	in	the	multivariable	model.		
	
In	 both	 analyses,	 to	 compare	 the	 predictive	 ability	 of	 ALBI	 versus	 CP	 score,	 c-
statistics	(concordance	statistics)	for	the	final	models	were	computed.		
	
Analyses	 were	 done	 using	 R	 version	 3.3.1.	 All	 p-values	 were	 two-sided	 with	
p<0.05	considered	statistically	significant.	
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Results	
	
Median	follow-up	of	the	102	available	patients	using	the	censoring	distribution	
was	 50.9	months	 (95%	 confidence	 interval	 (CI):38.9-60.6).	 	 Toxicity	 outcomes	
and	 dosimetric	 data	 were	 available	 for	 99	 patients,	 of	 whom	 26	 (26.3%)	
experienced	an	increase	in	CP	of	≥2	following	SBRT.		Of	the	99	patients	included	
in	the	toxicity	analysis,	four	were	classified	as	being	without	toxicity	on	the	basis	
of	 CP	 score	 increases	 <2	 and	 controlled	 HCC	 at	 approximately	 1	 month	 after	
SABR	 completion.	 All	 other	 patients	 (96%)	 had	 evaluation	 at	 3	 months.	 Four	
patients	who	developed	toxicity	also	experienced	mild	tumour	progression	(not	
meeting	RECIST	definition),	which	was	not	considered	a	confounding	factor	for	
toxicity.	 A	 further	 three	 patients	 included	 in	 the	 toxicity	 analysis	 developed	
progressive	 disease	within	 3	months	 but	 did	 not	 develop	 toxicity.	 No	 patients	
underwent	 transplant	 or	 any	 other	 liver	 directed	 therapies,	 nor	 re-irradiation,	
within	 this	 3	 month	 time	 period.	 No	 patients	 experienced	 classic	 radiation-
induced	liver	disease	(RILD)11.	One	included	patient,	with	intra-biliary	HCC,	who	
had	 toxicity	within	 3	months	 as	 defined	 above,	 also	 developed	 biliary	 toxicity,	
which	began	one	month	after	SBRT.	Two	patients,	who	were	excluded	from	the	
toxicity	analysis	on	account	of	no	dosimetric	data	being	available	and	insufficient	
follow	 up,	 also	 experienced	 progressive	 disease	 within	 three	 months.	
Characteristics	of	patients	overall	and	by	toxicity	outcome	are	shown	in	Table	1.	
Median	survival	was	16.9	months	(95%CI:	10.4-21.3	months),	with	1	and	3	year	
OS	of	54.6%	and	20.1%	respectively.	ALBI	grade	was	1	or	2	for	all	patients;	none	
were	categorised	grade	3.		
	
	
Relationship	between	ALBI	and	CP	scores	
	
Patients	with	higher	baseline	CP	scores	were	more	likely	to	have	higher	baseline	
ALBI	scores	(t-test	p<0.001)	and	ALBI	grades	(χ2	p<0.001).	
	
Fifty-two	 of	 fifty-six	 patients	 (92.8%)	 in	 ALBI	 group	 1	 had	 CP-A5	 disease	 and	
25/46	 patients	 (54.3%)	 in	 ALBI	 group	 2	 had	 CP-A6	 disease	 (Figure	 1	
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Supplementary	Material).	The	average	ALBI	in	patients	with	CP-A5	disease	was								
-2.74	and	-2.2	in	those	with	CP-A6	disease.	
	
Predictors	of	toxicity	
	
On	 univariate	 analysis,	 baseline	 CP	 score	 and	 ALBI,	 both	 as	 a	 continuous	 and	
binary	variable,	were	significant	predictors	of	toxicity	following	SBRT	(Table	2).	
In	 addition,	 platelet	 count,	 MLD,	 Veff,	 the	 biological	 NTCP	 and	 D800	 were	
significant	 on	univariate	 analysis.	Age,	 normal	 liver	 volume,	 tumour	 thrombus,	
prescribed	 dose	 and	 physical	 NTCP	 also	 reached	 the	 threshold	 for	 inclusion	
within	 the	multivariable	 analysis	 (i.e	p<0.2).	 Veff	was	 strongly	 correlated	with	
MLD	 (Pearson’s	 r=0.87),	 thus	 Veff	 was	 not	 carried	 into	 the	 multivariable	
analysis.	 All	 variables	 carried	 into	 the	multivariable	model	 had	 VIF<10.0,	 thus	
there	were	no	concerns	over	multi-collinearity.	
	
On	multivariable	analysis,	 including	ALBI	as	a	continuous	variable,	higher	ALBI	
values,	MLD	 and	 D800	 values	were	 significant	 predictors	 of	 toxicity	 occurring	
within	 three	 months	 of	 SBRT	 (ALBI	 odds	 ratio	 (OR):1.51,	 95%CI:1.23-1.85,	
p=0.000074;	 MLD	 OR:1.31,	 95%CI:1.02-1.68,	 p=0.036;	 D800	 OR:1.10,	
95%CI:1.01-1.20,	p=0.028;	Table	3).	Child	Pugh	score	A5	vs	A6	was	eliminated	
from	the	multivariable	model.	
	
On	 multivariate	 analysis,	 including	 ALBI	 as	 a	 binary	 variable,	 ALBI	 grade	
(OR:7.44;	 95%	 CI:2.34-23.70,	 p=0.00069)	 was	 the	 only	 statistically	 significant	
predictor	 of	 toxicity	 (Table	 3).	 Mean	 liver	 dose	 (OR:1.24,	 95%CI:0.985-1.56,	
p=0.07)	 and	D800	 (OR:1.08,	 95%CI:0.995-1.17,	p=0.066)	 remained	 in	 the	 final	
model	and	although	approaching,	did	not	reach,	statistical	significance.		
	
The	 final	 multivariable	 model	 using	 ALBI	 as	 a	 continuous	 variable	 had	 a	 c-
statistic	of	0.868,	 indicating	that	 this	model	has	very	good	predictive	ability	(c-
statistic=0.5	implies	a	model	does	no	better	at	predicting	outcome	than	chance).		
When	 ALBI	 was	 modelled	 as	 categorical,	 the	 c-statistic	 was	 0.831.	 The	 same	
model	replacing	ALBI	with	CP	score	had	a	predictive	ability	of	0.830.	
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Survival		
	
On	univariate	analysis,	including	all	102	patients,	ALBI	as	both	a	continuous	and	
categorical	variable	was	a	significant	predictor	of	OS	(Table	4).	Baseline	CP	score	
was	not	a	significant	predictor	of	OS	on	univariate	analysis	(p-value=0.063,	but	
below	the	threshold	for	inclusion	in	the	multivariable	analysis).	Age,	normal	liver	
volume,	 tumour	 thrombus,	 PS,	 Trial	 2	 vs	 1,	 and	MLD	were	 also	 significant	 on	
univariate	analysis.	In	addition,	gender,	tumour	volume	and	prescribed	dose	had	
p-values	 sufficient	 for	 inclusion	within	 the	multivariable	 analysis.	 All	 included	
variables	had	VIF	<10.0,	thus	there	were	no	concerns	over	multi-collinearity.	The	
development	of	toxicity	(as	defined	above)	was	also	noted	to	have	a	significant	
impact	 on	 OS,	 with	 median	 OS	 for	 patients	 with	 and	 without	 toxicity	 of	 5.1	
months	and	27.3	months	(p<0.001),	respectively.	This	factor	was	not	included	in	
the	multivariable	analysis,	however,	as	it	was	baseline	characteristics	that	were	
of	interest.	
	
Median	survivals	for	patients	in	ALBI	groups	1	and	2	were	19.8	and	8.5	months	
respectively	(Figure	1a;	log-rank	p=0.008).	In	contrast,	the	Kaplan-Meier	curves	
for	patients	with	CP-A5	and	CP-A6	disease	are	seen	 to	overlap	(Figure	1b;	 log-
rank	p=0.061,	median	survivals:	CP-A5:	17.5	months,	CP-A6:	10.4	months).	
	
On	multivariable	analysis	with	ALBI	as	a	continuous	variable,	tumour	thrombus	
(Hazard	ratio	(HR):1.94,	95%	CI:1.23-3.07,	p=0.004),	higher	ALBI	score	(HR	per	
0.1	 unit	 increase:1.09,	 95%CI:1.03-1.17,	 p=0.004)	 and	 being	 treated	 in	 Trial	 1	
compared	to	2	(HR:1.92,	95%CI:1.23-3.03,	p=0.004)	were	significant	predictors	
of	inferior	survival.		
	
On	 multivariable	 analysis	 with	 ALBI	 as	 a	 binary	 variable,	 tumour	 thrombus	
(HR:1.89,	 95%CI:1.20-2.98	 p=0.006),	 increased	 ALBI	 grade	 (HR:	 1.79,	
95%CI:1.14-2.80,	 p=0.011)	 and	 being	 in	 Trial	 1	 compared	 to	 2	 (HR:1.89,	
95%CI:1.20-2.94,	p=0.005)	were	predictive	of	inferior	OS.		
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The	c-statistics	from	models	using	ALBI	as	continuous	and	categorical	variables	
were	 0.643	 and	 0.628,	 respectively.	 The	 c-statistic	 from	 the	 model	 replacing	
ALBI	with	CP	score	was	0.625.		
	
	
	
Discussion	
	
	
This	report	evaluated	the	ALBI	scoring	system	as	a	potential	prognostic	marker	
in	HCC	patients	with	CP-A	liver	disease	treated	with	6-fraction	SBRT	within	two	
prospective	trials.	The	ALBI	scoring	system	was	also	evaluated	as	a	predictor	of	
toxicity.	 In	 addition,	 this	 project	 aimed	 to	 establish	 if	 the	 inclusion	 of	 ALBI	 in	
survival	 analyses	 could	 account	 for	 the	 previously	 observed	 OS	 differences	
between	patients	treated	in	Trial	1	and	28.	On	multivariable	analysis	for	survival,	
baseline	 ALBI,	 both	 as	 a	 continuous	 and	 binary	 variable,	 was	 an	 independent	
prognostic	 factor.	 Furthermore,	 the	 ALBI	 system	 proved	 more	 discriminating	
than	 CP	 score	 (A5	 vs	 A6)	 in	 determining	 OS,	 with	 ALBI	 remaining	 in	
multivariable	models,	while	 CP	 score	was	 thrown	out,	 and	ALBI-based	models	
having	marginally	 superior	 c-statistics.	 The	 previously	 observed	 differences	 in	
outcome	 between	 patients	 in	 Trial	 1	 or	 2	 remained	 significant,	 despite	 the	
addition	 of	 ALBI	 and	 therefore	 this	 difference	 remains	 unexplained.	 This	
observation,	 however,	 is	 likely	 multifactorial,	 perhaps	 relating	 to	 a	 learning	
curve	 and	 evolution	 of	 radiation	 imaging,	 planning,	 delivery	 and	 image-guided	
radiotherapy	over	the	time	period	of	the	studies8.	In	addition,	as	observed	in	the	
original	 analysis8,	 tumour	 thrombus	 remained	 an	 independent	 detrimental	
factor	for	OS.	
	
As	 in	 the	 original	 ALBI	 publication,	 the	 use	 of	 ALBI	 grade	 allowed	 the	
identification	 of	 two	 distinct	 prognostic	 groups	 within	 the	 category	 of	 CP-A	
disease,	with	 those	 in	ALBI	group	1	and	2	experiencing	median	survivals	of	26	
and	14	months,	respectively4.	In	this	current	report,	examining	Western	patients	
managed	with	SBRT,	patients	in	ALBI	group	1	and	2	had	median	survivals	of	19.8	
and	 8.5	 months	 respectively	 (p=0.008;	 and	 CP-A5	 and	 CP-A6	 patients	 had	
median	survivals	of	17.5	and	10.4	months	respectively,	p=0.061).	All	patients	in	
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this	report	were	deemed	unsuitable	for	transplant,	resection,	TACE	or	RFA,	with	
55%	having	macrovascular	invasion,	and	as	such	would	be	expected	to	fare	less	
well	 than	 those	 suitable	 for	 established	 treatments8.	 Other	 groups	 have	 also	
found	ALBI	 grade	 to	be	useful	 in	 determining	outcomes	 amongst	HCC	patients	
undergoing	liver	resection,	TACE,	radioembolization	and	systemic	therapies,	and	
frequently	 ALBI	 is	more	 discriminating	 than	 CP	 scores13-17.	 Other	 groups	 have	
also	 investigated	 the	 incorporation	 of	 ALBI	 within	 other	 recognised	 staging	
systems18,19.	Until	recently,	however,	ALBI	as	a	prognostic	indicator	has	not	been	
specifically	 investigated	 in	 the	 setting	 of	 SBRT.	 Another	 report,	 investigating	
ALBI	 in	 a	 smaller	 prospective	 cohort	 of	 40	 HCC	 patients	 treated	with	 SBRT20,	
found	 that	 a	 worsening	 of	 ALBI	 by	 0.5	 after	 SBRT	 was	 predictive	 of	 inferior	
survival,	while,	interestingly,	the	baseline	ALBI	grade	was	not	predictive	of	OS20.	
This	is	in	contrast	to	the	evaluation	presented	here	and	could	be	as	a	result	of	the	
smaller	number	of	patients	(40)	included	in	the	study	by	Toesca	et	al	and/or	as	a	
result	 of	 the	 loss	 of	 information	when	 discretising	 the	 ALBI	 score.	 In	 keeping	
with	 this	 current	 study,	 however,	 baseline	 CP	 was	 also	 not	 found	 to	 be	 a	
significant	predictor	of	OS20.	 A	 recent	 retrospective	 analysis	 of	Taiwanese	HCC	
patients	treated	with	SBRT	found	ALBI	grade	2	vs.	1	to	be	a	significant	predictor	
of	OS	on	univariate	(but	not	multivariable)	analysis	and	both	ALBI	and	CP	were	
found	effective	in	predicting	radiation-induced	liver	disease21.	The	retrospective	
nature,	shorter	median	follow-up	and	smaller	proportion	(38%)	of	patients	with	
macrovascular	invasion	in	the	above	analysis	make	this	a	different	population	to	
the	prospective	series	presented	here.		
	
In	 addition	 to	 being	 predictive	 of	 OS,	 baseline	 ALBI	 was	 predictive	 of	 toxicity	
following	 SBRT	 and	 also	 outperformed	 CP	 classification	 for	 this	 purpose,	with	
ALBI	 remaining	 in	 multivariate	 models	 and	 displaying	 marginally	 superior	 c-
statistics.	 	 Thus,	 it	 appears	 likely	 that	 ALBI	 grade,	 with	 less	 subjectivity	 and	
fewer	components	than	CP,	may	be	a	marker	of	prognosis	and	toxicity	useful	for	
treatment	 selection	 and	 stratification	 within	 trials.	 Although	 calculated	 as	 a	
continuous	 variable,	 and	 accepting	 that	 some	 information	 is	 lost	 in	 the	
discretising	 process,	 the	 use	 of	 ALBI	 grade	 facilitates	 practical	 clinical	
application,	 without	 loss	 of	 significance	 as	 a	 prognostic	 or	 toxicity-predictive	
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value.	 	One	limitation	of	ALBI	is	the	need	for	a	calculation	algorithm,	relative	to	
CP	score,	which	can	be	manually	computed.	
	
Consistent	 with	 our	 previous	 toxicity	 analysis9,	 mean	 liver	 dose	 and	 D800	
remained	significant	predictors	of	toxicity	when	analysing	ALBI	as	a	continuous	
variable.	 	Mean	 liver	dose	and	 the	 low	dose	region	of	 the	 liver	DVH	curve	 (e.g.	
D800)	have	also	been	shown	in	other	series	to	be	related	to	liver	toxicity11,22,23.	
Although,	 mean	 liver	 dose	 and	 D800	 were	 not	 statistically	 significant	 when	
including	ALBI	as	a	dichotomous	variable	in	the	toxicity	analysis,	likely	the	result	
of	 statistical	 variability	 and	 a	 loss	 of	 statistical	 power	when	dichotomising	 the	
variable,	 these	 factors	 did	 approach	 significance,	 again	 reflecting	 their	
importance	 in	 liver	 toxicity	 risk.	 In	 addition	 to	 ALBI,	 the	 presence	 of	 tumour	
thrombus	was	identified	as	an	independent	predictor	of	inferior	survival	in	this	
series.	 The	 importance	 of	 this	 factor	 as	 a	 negative	 prognostic	 feature	 is	 well	
established	and	not	surprising24,25.	
	
This	work	 has	 limitations:	 a	 greater	 number	 of	 patients	 is	 required	 to	 further	
evaluate	ALBI,	especially	 in	patients	with	more	advanced	 liver	dysfunction:	 the	
value	 of	 ALBI	 in	 patients	with	 CP-B	 and	 CP-C	HCC	 is	 unknown.	 That	 said,	 this	
report	is	consistent	with	other	literature	examining	ALBI	in	HCC,	predominantly	
treated	 with	 other	 therapies,	 and	 this	 is	 the	 largest	 investigating	 ALBI	 in	 the	
setting	of	SBRT	in	a	prospective	Western	population.	Another	limitation	is	a	lack	
of	 information	regarding	 the	details	of	previous	 liver	directed	 therapies	on	 the	
risk	 of	 toxicity	 following	 SBRT.	 	 The	 use	 of	 previous	 liver	 directed	 therapies,	
however,	was	not	found	to	be	significant	in	this	series,	but	could	be	considered	in	
future	 investigations.	 ALBI	 could	 also	 be	 investigated	 with	 regard	 to	 other	
outcome	measures	(e.g.	progression	free	survival)	and	the	impact	of	changes	in	
ALBI	on	outcome.	
	
In	 conclusion,	 in	 patients	 with	 Child	 Pugh	 A	 liver	 disease,	 baseline	 ALBI	 was	
identified	as	an	independent	prognostic	 factor	 in	Western	HCC	patients	treated	
with	SBRT.	ALBI	was	also	predictive	of	toxicity	following	SBRT.	For	both	survival	
and	 toxicity,	ALBI	proved	more	discriminating	 than	CP	score.	ALBI	grades	may	
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prove	useful	in	patient	selection	for	SBRT	as	a	potential	prognostic	marker	and	
as	 a	 marker	 for	 toxicity,	 and	 therefore	 should	 be	 included	 as	 a	 patient	
stratification	factor	in	future	clinical	trials.	
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Figure	and	table	legends	
	
Figure	1.	a)	Survival	in	ALBI	groups	1	and	2	and	b)	Survival	in	CP	class	A5	and	A6		
	
Table	1.	Baseline	characteristics	
	
Table	2.	Univariate	logistic	regression	for	toxicity	
	
Table	3.	Multivariate	logistic	regression	for	toxicity	
	
Table	4.	Univariate	Cox	regression	for	overall	survival	
	
Table	5.	Mulitvariate	Cox	regression	for	overall	survival		
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Table	1.	Baseline	characteristics	
	
Patient	and	disease	factors	
	 Overall	(n=102)	 Toxicity	analysis	(n=99)	
Patients	with	toxicity	
(n=26)	
Patients	without	
toxicity	(n=73)	
	 n	 %	 n	 %	 n	 %	
Age	(years)	
					Median	
					Range	
	
69.4	
40.4-90.3	
	
67.31	
40.4-83.8	
	
71.76	
45.8-90.3	
Gender	
					Male	
					Female	
	
80	
22	
	
78%	
22%	
	
21	
5	
	
81%	
19%	
	
58	
15	
	
80%	
21%	
Tumour	volume	(cc)	
					Median	
					Range	
	
123.1	
1.3-1913.14		
	
136.2	
2-1735	
	
106.9	
1-1913	
Normal	liver	
volume*	(cc)	
					Median	
					Range	
	
	
1270.7		
766.5-	3966.8		
	
	
1637	
870-2278	
	
	
1230	
767-3967	
Macrovascular	HCC	
invasion	
					Yes	
					No	
	
	
56	
46	
	
	
55%		
45%	
	
	
18	
8	
	
	
69%	
31%	
	
	
35	
38	
	
	
48%	
52%	
Baseline	Child	Pugh	
class	
					A5	
					A6	
	
	
73		
29		
	
	
72%	
28%	
	
	
13	
13	
	
	
50	
50	
	
	
58	
15	
	
	
80%	
21%	
Baseline	ALBI	grade	
					Median	
					Range	
	
						
					Group	1	
					Group	2	
	
-2.63	
-3.40-	-
1.64	
	
56	
46	
	
	
	
	
	
55%	
45%	
	
-2.35	
-2.8-	-1.6	
	
	
6	
20	
	
	
	
	
	
23%	
77%	
	
-2.71	
-3.4-	-
1.9	
	
49	
24	
	
	
	
	
	
67%	
33%	
Baseline	platelet	
count	
					Median	
					Range	
	
	
141	
55-834	
	
	
108	
55-328	
	
	
151	
62-834	
Underlying	liver	
disease	
					Hepatitis	B	
					Hepatitis	C	
					Other	
	
	
39**	
31	
32	
	
	
38%	
30.%	
31%	
	
	
8	
9	
9	
	
	
31%	
35%	
35%	
	
	
29	
22	
22	
	
	
40%	
30%	
30%	
Baseline	AFP	
					Median	
					Range	
	
163	
<6-714500		
	 	
503	
<6-167850	
	
125	
<6-714500	
ECOG	performance	
status	
					0	
					1	
					2	
	
	
50		
40	
12		
	
	
49%	
39%	
12%	
	
	
14	
9	
3	
	
	
54%	
35%	
12%	
	
	
36	
31	
6	
	
	
49%	
42%	
8%	
Extra-hepatic	
disease	
					Absent	
					Present	
	
	
90	
12		
	
	
88%	
12%	
	
	
21	
5	
	
	
81%	
19%	
	
	
67	
6	
	
	
92%	
8%	
Previous	liver	
directed	therapy†	
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					Surgery	
					TACE	
					RFA	
					PEI	
					Any	
					None	
	
9	
22	
35	
16	
51	
51	
9%	
22%	
34%	
16%	
50%	
50%	
6	
6	
8	
3	
12	
14	
23%	
23%	
31%	
12%	
46%	
54%	
	
3	
16	
27	
12	
38	
35	
4%	
22%	
37%	
16%	
52%	
48%	
Trial	
					1	
					2	
	
50	
52	
	
49%	
51%	
	
13	
13	
	
50%	
50%	
	
34	
39	
	
47%	
53%	
Dosimetric	factors	(	6	fractions)	
Prescribed	dose	
(Gy)	
					Median	
					Range	
	
36		
24-54		
	
34.5	
25.8-54	
	
36.6	
24-54	
Mean	liver	dose	
(Gy)††	
				Median	
					Range	
	
16.0		
4.3-21.4	
	
16.96	
9.6-20.71	
	
15.26	
4.3-21.1	
Veff	
					Median	
					Range	
	
0.43		
0.09-0.80		
	
0.508	
0.2-0.8	
	
0.4088	
0.09-0.7	
Physical	NTCP	(%)	
					Median	
					Range	
	
12.8	
0-92.4	
	
15.6	
0-92.4	
	
10.7	
0-61.5	
Biological	NTCP	(%)	
					Median	
					Range	
	
0.8	
0-18.9	
	
2.8	
0-18.3	
	
0.6	
0-18.9	
D800	(Gy)	
					Median	
					Range	
	
7.45	
0-28.9	
	
14.25	
1.8-28.9	
	
5.95	
0-27.9	
*Normal	liver	volume	was	the	total	liver	volume	minus	GTV	
**8	had	coexistent	Hepatitis	C	
†	More	than	one	therapy	may	apply	
††	Mean	liver	dose	was	based	on	dose	received	by	liver	minus	GTV	
TACE:	trans-arterial	chemo-embolization,	RFA:	radiofrequency	ablation,	PEI:	
percutaneous	ethanol	injection	
Note.	3	patients	excluded	from	toxicity	analysis	as	no	dosimetric	data	available	
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Table	2.	Univariate	logistic	regression	for	liver	toxicity	
	
	 	 Univariate	analysis	
Patient	details	 Odds	radio		
(95%	confidence	interval)	
p	value	
(p<0.2	carried	into	
multivariate	
analysis*)	
	 Age	 0.97	(0.94-1.01)	 0.18*	
	 Gender		
(Female	vs	Male)	
	 0.89	
	 Total	tumour	volume	
(per	100cc	increase)	
	 0.42	
	 Normal	liver	volume	
(per	1000cc	increase)	
1.92	(0.75-4.90)	 0.17*	
	 Thrombus	(Yes	vs	No)	 2.44	(0.94-	6.32)		 0.066*	
	 Baseline	Child	Pugh	
(A6	vs	A5)	
3.87	(1.49-	10.10)		 0.0055*	
	 Baseline	platelet	count	 0.991	(0.98-	0.998)	 0.018*	
	 Underlying	liver	
disease	
(Hepatits	C	vs	
hepatitis	B)	
(Other		vs	hepatitis	B)	
	 0.721		
	 Previous	liver	directed	
therapy	
					Any	vs	none	
	
	
0.79	(0.32-1.94)	
	
	
0.61	
	 Baseline	ALBI	(0.1	unit	
increase;	continuous	
variable)	
1.37	(1.17-1.60)	 <0.0001*	
	 Baseline	ALBI	
Grade	2	vs	1	
	(ordinal	variable)	
6.81	(2.42-	19.20)	 0.00028*	
SBRT	treatment	details	 	 	
	 Prescribed	dose	 0.95	(0.89-1.02)	 0.160*		
	 Mean	liver	dose†	 1.31	(1.08-1.59)		 0.0052*	
	 Veff	(0.1	unit	increase)	 1.66	(1.16-2.38)		 0.0054**	
	 Physical	NTCP	 1.02	(0.996-1.04)	 0.11	
	 Biological	NTCP	 1.11	(1.02-1.20)		 0.016*	
	 D800		 1.12	(1.05-1.20)		 0.00052*	
*	Included	in	multivariate	analysis,	odds	ratios	and	confidence	intervals	only	
shown	for	variables	with	p<0.2.	
**Not	included	in	multivariate	analysis	to	avoid	multicollinearity	as	strongly	
correlated	with	mean	liver	dose.	
†	Mean	liver	dose	was	based	on	dose	received	by	liver	minus	GTV	
NTCP:	normal	complication	probability	
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Table	3.	Multivariate	logistic	regression	for	toxicity	
	
	
	 	Odds	ratio		
(95%	confidence	interval)	
p	value	
	
Model	using	ALBI	as	continuous	variable	
	 Baseline	ALBI	(0.1	unit	
increase;	continuous	
variable)	
1.51	(1.23-1.85)	 0.000074	
	 Mean	liver	dose*	 1.31	(1.02-1.68)	 0.036	
	 D800	 1.10	(1.01-1.20)	 0.028	
Model	using	ALBI	as	ordinal	variable	
	 Baseline	ALBI	
Grade	2	vs	1	
(ordinal	variable)	
7.44	(2.34-	23.70)	 0.00069	
	 Mean	liver	dose*	 1.24	(0.985-1.56)	 0.07	
	 D800	 1.08	(0.995-1.17)	 0.066	
	
Note.	Mean	liver	dose	was	forced	into	the	final	model	given	the	general	
acceptance	of	its	importance	in	predicting	toxicity	
*	Mean	liver	dose	was	based	on	dose	received	by	liver	minus	GTV	
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Table	4.	Univariate	Cox	regression	for	overall	survival	
	
Patient	details	 Hazard	ratio		
(95%	confidence	interval)	
p	value	
(p<0.2	carried	
into	multivariate	
analysis*)	
	 Age	 0.980	(0.96-0.999)		 0.036*	
	 Gender	(Male	vs	Female)	 1.56	(0.88-2.80)	 0.130*	
	 Tumor	volume	(per	100cc	
increase)	
1.05	(0.999-1.100)		 0.055*	
	 Normal	liver	volume	(per	
1000cc	increase)	
1.55	(1.06-2.28))	 0.024*	
	 Thrombus	(Yes	vs	No)	 1.77	(1.13-2.78)		 0.012*	
	 Baseline	Child	Pugh		
(6	vs	5)	
1.58	(0.98-	2.54)		 0.063*	
	 Baseline	platelet	count		 	 0.23	
	 Underlying	liver	disease	
(Hepatits	C	vs	hepatitis	B)	
(Other		vs	hepatitis	B)	
	 0.648	
	
	 Baseline	AFP	
(per	10,000	unit	increase)	
	 0.51	
	 Baseline	ECOG	
Performance	status	
					1	vs	0	
					
					2	vs	0	
	
	
2.00	(1.24-3.23)	
	
2.22	(1.05-4.70)	
	
	
0.004*	
	
0.036*	
	 Extra-hepatic	disease	(yes	
vs	No)	
	 0.20		
	 Trial	(2	vs	1)	 0.57	(0.37-0.89)	 0.013*	
	 Baseline	ALBI	(0.1	unit	
increase;	continuous	
variable)	
1.090	(1.026-1.158)	 0.005*	
	 Baseline	ALBI		
Grade	2	vs	1	
(ordinal	variable)	
	
1.809	(1.157-2.827)	 0.009*	
SBRT	treatment	details	 	 	
	 Prescribed	dose	 0.98	(0.95-1.01)	 0.10*	
	 Mean	liver	dose**	 1.11(1.02-1.20)		 0.012*	
*Variables	with	p<0.2	(shown	in	bold	text)	included	in	multivariate	analysis,	
hazard	ratios	and	confidence	intervals	only	shown	for	variables	with	p<0.2	
**	Mean	liver	dose	was	based	on	dose	received	by	liver	minus	GTV	
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Table	5.	Mulitvariate	Cox	regression	for	overall	survival		
	
Factor	 	Hazard	ratio	 p	value	
Model	using	ALBI	as	continuous	variable	
	 Thrombus	(Yes	vs	No)	 1.94	(1.23-3.07)	 0.004	
	 Baseline	ALBI	(0.1	unit	
increase;	continuous	
variable)	
1.09	(1.03-	1.17)	 0.004	
	 Trial	(2	vs	1)	 0.52	(0.33-0.81)	 0.004	
Model	using	ALBI	as	ordinal	variable	
	 Thrombus	(Yes	vs	No)	 1.89	(1.20-2.98)	 0.006	
	 Baseline	ALBI		
Grade	2	vs	1	
(ordinal	variable)	
	
1.79	(1.14-2.80)	 0.011	
	 Trial	(2	vs	1)	 0.53	(0.34-0.83)	 0.005	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 27	
	
	
	
	
Figure	1.	a)	Survival	in	ALBI	grades	1	and	2	and	b)	Survival	in	CP	class	A5	and	A6		
	
	
	
	
	
	
	
a) 
b) 
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Supplementary	Material	
	
Figure	 1.	 Relationship	 between	 ALBI	 as	 a	 continuous	 variable	 and	 Child	 Pugh	
score	 (independent	 samples	 t-test	 p<0.01;	 data	 jittered	 to	 illustrate	 spread	 of	
results,	 red	 solid	 circles	 represent	 those	 with	 toxicity	 and	 blue	 open	 circles	
represent	those	without	toxicity)	
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